Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, shares her highlights of the European Society for Medical Oncology (ESMO) 2023 Congress, noting the important clinical implications of the Phase III KEYNOTE-A18 (NCT04221945) trial, as well as noting data supporting the combination of PARP inhibitors and immune therapy in the treatment of patients with endometrial cancer with mismatch repair deficiency (dMMR). This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть